Overview

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety of INO-1001 in subjects who have experienced a heart attack and are to be treated with coronary angioplasty.
Phase:
Phase 2
Details
Lead Sponsor:
Inotek Pharmaceuticals Corporation